# DREAMM-10 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/dreamm-10

> The next catalyst for DREAMM-10, sponsored by GSK plc (GSK), is its interim data readout, early 2028.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What is the next FDA catalyst for DREAMM-10?

The next catalyst for DREAMM-10, sponsored by GSK plc (GSK), is its interim data readout, early 2028. SEC Form 8-K: "Interim efficacy and safety data for Blenrep as a first line treatment are expected in early 2028 with enrolment expanded to US sites to increase US patient representation in the study population." [Calendar and source filings](https://sec-api.dev/pdufa/dreamm-10)

Source: SEC Form 8-K, accession 0001654954-25-012307, https://www.sec.gov/Archives/edgar/data/1131399/000165495425012307/a1902f-gskoriginaledgar.htm (retrieved 2026-11-12). Last confirmed 2025-10-29. Cite: https://sec-api.dev/pdufa/dreamm-10#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | DREAMM-10 |
| Codes | DREAMM-10 |
| Sponsor | GSK plc (GSK) https://sec-api.dev/companies/gsk/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### early 2028: interim data readout

- Status: scheduled. Date confidence: half.
- First seen 2025-10-24, last confirmed 2025-10-29.
- SEC Form 8-K (accession 0001654954-25-012307): "Interim efficacy and safety data for Blenrep as a first line treatment are expected in early 2028 with enrolment expanded to US sites to increase US patient representation in the study population." https://www.sec.gov/Archives/edgar/data/1131399/000165495425012307/a1902f-gskoriginaledgar.htm
- SEC Form 8-K (accession 0001654954-25-012176): "Q4-2024.4 Interim efficacy and safety data for Blenrep as a first line treatment are expected in early 2028 with enrolment expanded to US sites to increase US patient representation in the study population." https://www.sec.gov/Archives/edgar/data/1131399/000165495425012176/a6592e.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/dreamm-10.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "DREAMM-10 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/dreamm-10

```bibtex
@misc{secapidev_pdufa_dreamm_10_20261116,
  title        = {DREAMM-10 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/dreamm-10}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_dreamm_10_20261116","title":"DREAMM-10 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/dreamm-10","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
